Capricor Therapeutics, Inc.
CAPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -11.5% | 886.8% | 941.8% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -124.4% | -44.8% | -755.1% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -184.7% | -91.4% | -1,143% | -8,449.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -181.7% | -88.5% | -1,137.4% | -8,175.9% |
| EPS Diluted | -1.15 | -0.83 | -1.18 | -0.87 |
| % Growth | -38.6% | 29.7% | -35.6% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |